Skip to main content
Fig. 5 | Respiratory Research

Fig. 5

From: Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma

Fig. 5

The pharmacokinetic and pharmacodynamic effects of the trivalent IL-5-HSA Nb in cynomolgus monkeys. A Schematic representation of its pharmacokinetic and pharmacodynamic study. B The pharmacokinetic effect of the trivalent IL-5-HSA Nb in cynomolgus monkeys with the primary doses of 5 mg/kg and 2 mg/kg. The plasma concentration of trivalent IL-5-HSA Nb was measured within 56 days. C The inhibitory effect of the trivalent IL-5-HSA Nb on eosinophil (EOS) numbers was determined within 84 days

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us